Multiplikator Forward P/S: ReShape Lifesciences, Inc. (RSLS)

ReShape Lifesciences (RSLS) relies on the precision final assembly of weight loss systems while maintaining moderate procurement of external components. However, poor scalability and certification costs are keeping margins at zero. The implementation of ESG standards is optimizing production energy costs. This chart of the projected P/S from the GURU.Markets terminal shows that 1.60 forms the current metric value.

To minimize risks during fundamental analysis, it is essential to correlate an asset's market value with expected sales expansion rates. In the case of ReShape Lifesciences (RSLS), an aggressive commercial strategy and a reliance on high-compensated medical sales representatives make the business's future P/S ratio a key indicator of investment viability. This metric divides current market capitalization by projected annual revenue, determining the cost of one dollar of future earnings.